TuHURA Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HURA | CHRS | IPHA | VRXA | MGNX | PYXS | |
|---|---|---|---|---|---|---|
| Market cap | 109.61M | 131.36M | 159.17M | 134.34M | 147.15M | 198.30M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.8 | -1.3 | -3.0 | — | -1.6 | -1.5 |
| Price/book | 6.0 | 2.2 | -2.9 | -0.7 | 3.4 | 9.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −29.80% | −42.95% | −26.92% | −90.96% | +61.81% | −58.06% |
| Today | +3.93% | +5.54% | +5.56% | −4.04% | −0.86% | +1.22% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All HURA news ›TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
Nov 04, 2026, 09:15 ET Presentations highlight the role of the Delta Opioid Receptor (DOR) as a novel target central to the regulation of multiple genes involved in immune suppression, chemotaxis and proliferation of immune suppressing…
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
Oct 26, 2026, 07:30 ET Preliminary results demonstrate major objective tumor responses in first 3 patients at 6 months Company to host a webcast today, October 26, 2026, at 8:30 am ET The primary endpoint of the study is safety and…
Tuhura Biosciences Receives New U.S. Patent Broadening Coverage for Its Vista Inhibitor, Tbs-2025
www.marketscreener.com announced that the United States Patent and Trademark Office (USPTO) has issued Patent No 12,760,104 entitled, "Anti-VISTA Antibodies and Uses Thereof." The new patent claims pro
TuHURA Biosciences, Inc.: Latest Headlines - Nasdaq Stock Exchange
Find the latest highlights on TuHURA Biosciences, Inc. at the Nasdaq stock exchange. Highlights TuHURA Biosciences, Inc. Biotechnology & Medical Research All financial news and data tailored to specific country editions
TuHURA Biosciences, Inc.: Relative Strength Chart - Stock Nasdaq
Compare TuHURA Biosciences, Inc. with the company of your choice via a Relative Strength chart. Real-time HURA price, Nasdaq stock exchange Relative Strength Chart TuHURA Biosciences, Inc. Biotechnology & Medical Research All financial…
TuHURA Biosciences, Inc. (NASDAQ:HURA) Stock Has Consensus Target Price of $9.00
Posted by Michael Walen on Oct 12th, 2026 A number of analysts have recently commented on HURA shares. Citizens Jmp restated a “market outperform” rating and set a $9.00 target price on shares of TuHURA Biosciences in a report on Tuesday,…
All Transcripts on TuHURA Biosciences, Inc. (HURA)
Find all the latest transcripts on TuHURA Biosciences, Inc. Transcripts TuHURA Biosciences, Inc. Biotechnology & Medical Research All financial news and data tailored to specific country editions
TuHURA Biosciences, Inc.: Official Announcements - Stock Market News
Find the latest press releases and official documents published by TuHURA Biosciences, Inc. on MarketScreener. Press Releases TuHURA Biosciences, Inc. Biotechnology & Medical Research All financial news and data tailored to specific…
TuHURA Biosciences, Inc.(NasdaqCM: HURA) dropped from Russell 2500 Index
TuHURA Biosciences, Inc. dropped from Russell 2500 Index... Biotechnology & Medical Research TuHURA Biosciences, Inc.(NasdaqCM:HURA) dropped from Russell 2500 Index
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com11
- prnewswire.com2
- stocktitan.net2
- tradingview.com2
- pluang.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 19 articles, not a forecast.